Efficacy of hepatitis B immunization with reduced intradermal doses

Area of Science:

• Hepatology
• Immunology
• Vaccinology

Background:

• Hepatitis B virus (HBV) infection remains a significant global health concern.
• Standard vaccine administration protocols exist for HBV vaccines like HB-Vax and Hevac-B.
• Optimizing vaccine efficacy and patient tolerance is an ongoing area of research.

Purpose of the Study:

• To evaluate the immunogenicity, efficacy, and safety of reduced-dose intradermal (I.D.) hepatitis B vaccines.
• To compare experimental I.D. vaccination regimens with standard protocols for HB-Vax and Hevac-B.
• To assess seroconversion rates and anti-HBs titres post-vaccination.

Main Methods:

• A total of 462 healthy subjects were enrolled.
• Vaccination groups included standard regimens and experimental I.D. reduced doses (2 mcg HB-Vax, 1 mcg and 0.5 mcg Hevac-B).
• Post-vaccination serological markers for HBV were monitored for up to 360 days.

Main Results:

• Reduced I.D. doses of both HB-Vax and Hevac-B demonstrated high immune responses and generally greater efficacy than standard protocols.
• At 90 days, seroconversion rates for reduced I.D. HB-Vax were 80.8% and 82.7%, compared to 62.0% for standard protocol.
• Reduced I.D. Hevac-B achieved 90-day seroconversion rates of 92.0%, 87.9%, and 94.1% (minimal dose), surpassing the standard 83.8% rate.

Conclusions:

• Reduced-dose intradermal administration of HB-Vax and Hevac-B is a safe and effective alternative to standard protocols.
• Experimental I.D. regimens elicit robust immune responses, often exceeding those of conventional administration.
• Further investigation into optimized I.D. vaccination schedules for hepatitis B may improve public health outcomes.